Additionally, terminal sample analysis revealed TCB-induced effector cell PD1 expression, combined with increased PDL1 expression by the tumor cells, suggesting an adaptive immune resistance mechanism, also observed in other preclinical TCB studies (31–33), and prompting us to evaluate the impact of blocking PDL1 in vivo. Here, CD274 is linked to neoplasm.